Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.82
- Piotroski Score 6.00
- Grade Overweight
- Symbol (ALKS)
- Company Alkermes plc
- Price $28.00
- Changes Percentage (1.69%)
- Change $0.47
- Day Low $27.33
- Day High $28.07
- Year High $32.88
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/23/2024
- Fiscal Year End N/A
- Average Stock Price Target $35.00
- High Stock Price Target $50.00
- Low Stock Price Target $27.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $3.36
- Trailing P/E Ratio 7.12
- Forward P/E Ratio 7.12
- P/E Growth 7.12
- Net Income $355.76 M
Income Statement
Quarterly
Annual
Latest News of ALKS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Arteta talks up Enrique's 'unbelievable power' as Arsenal hosts PSG in marquee Champions League game
Arsenal manager Mikel Arteta praises Luis Enrique, reminiscing their time at Barcelona and acknowledging his impact as a coach. Arteta admires Enrique's personality, energy, and team-building skills a...
By AP NEWS | 20 hours ago -
US East Coast port strike looms Tuesday with no talks scheduled
A potential strike by U.S. East and Gulf Coast port workers may halt container traffic from Maine to Texas, costing the economy up to $5 billion a day. The labor contract between the ILA union and USM...
By Yahoo! Finance | 22 hours ago -
China holds military drills in South China Sea after talks with U.S
By Joe CashBEIJING (Reuters) -Chinese air and naval forces are conducting manoeuvres in a disputed area of the South China Sea, the military said on Saturday, hours after the country's top diplomat di...
By Reuters | 3 days ago